Loading stock data…
$2.78-0.02 (-0.71%)
Lexaria Bioscience Corp.
Lexaria Bioscience Corp. in the Healthcare sector is trading at $2.78 with a market capitalization of $15M. Wall Street consensus targets $82.50 (1 analysts), implying a +2867.6% move over the next 12 months. The stock is currently near its 52-week low of $2.55, remaining 70.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $20,000 | $0↓ | $174,000 | $174,000 |
| Gross Profit | $0↓ | $20,000 | $0↓ | $174,000 | $174,000 |
| Operating Income | -$1.99M↓ | -$1.45M↑ | -$1.57M↑ | -$2.69M↑ | -$3.75M |
| Net Income | -$1.99M↓ | -$1.45M↑ | -$1.60M↑ | -$2.70M↑ | -$3.79M |
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich tr...